Biogen Inc. (NASDAQ:BIIB), a $20.8 billion ... the United States and Europe are now reviewing a higher dose regimen of nusinersen, a drug designed to treat spinal muscular atrophy (SMA).

Simultaneously, Biogen is under review by the FDA and EMA for a higher dose regimen of the same SMA drug, nusinersen. The company has maintained a positive outlook with an Outperform rating from ...

Biogen (BIIB) announced that the U.S. Food ... has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy, SMA. The higher dose regimen of nusinersen ...

Biogen Safe Harbor This news release contains forward-looking statements, including related to the potential clinical effects of a higher dose regimen of nusinersen; the potential benefits ...

FY24 EPS is projected at $16.34. The FDA approved maintenance dosing regimen for Leqembi in Alzheimer's, while Biogen's nusinersen higher-dose regimen is under review. Every week, our Whisper ...

Biogen has invested heavily in its Alzheimer ... at a time when its big selling SMA drug Spinraza (nusinersen) is facing increased competitive pressure. At the same time, Sage has struggled ...

Biogen's strategy has its roots in the 2003 ... Ocrevus royalties are based on peak sales of $9 billion. For Spinraza (nusinersen), sales began to decline in 2020 as new patients and treated ...

and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

Royalty also holds rights on Biogen’s MS medication Tysabri (natalizumab) and spinal muscular atrophy drug Spinraza (nusinersen), acquired through agreements with Ionis and Perrigo. The deal ...

Biotech giant Biogen Inc (NASDAQ:BIIB ... marketing applications seeking approval for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen ...